Edition:
India

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

3.66USD
18 Oct 2019
Change (% chg)

$-0.08 (-2.01%)
Prev Close
$3.74
Open
$3.71
Day's High
$3.81
Day's Low
$3.65
Volume
704,720
Avg. Vol
826,060
52-wk High
$6.09
52-wk Low
$1.83

Latest Key Developments (Source: Significant Developments)

Therapeuticsmd Q2 Loss Per Share $0.19 Excluding Items
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.19 EXCLUDING ITEMS.SEES FY 2019 REVENUE $29.45 MILLION TO $34.2 MILLION.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.RAISES FULL-YEAR NET REVENUE GUIDANCE TO RANGE OF $29.45 MILLION TO $34.20 MILLION.AS OF JUNE 30, 2019, COMPANY'S CASH ON HAND TOTALED ABOUT $182.8 MILLION, COMPARED WITH ABOUT $161.6 MILLION AT DECEMBER 31, 2018.  Full Article

TherapeuticsMD And Theramex Enter Into Exclusive License And Supply Agreement To Commercialize Bijuva And Imvexxy
Friday, 7 Jun 2019 

June 7 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD AND THERAMEX ENTER INTO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT TO COMMERCIALIZE BIJUVA™ AND IMVEXXY® OUTSIDE THE UNITED STATES.THERAPEUTICSMD INC - AGREEMENT LEVERAGES THERAMEX'S EXTENSIVE WOMEN'S HEALTH CAPABILITIES AND INFRASTRUCTURE TO BENEFIT OF MENOPAUSAL WOMEN OUTSIDE OF U.S..THERAPEUTICSMD INC - THERAPEUTICSMD TO RECEIVE EUR 14 MILLION AS AN UPFRONT FEE.THERAPEUTICSMD INC - IS ELIGIBLE TO RECEIVE UP TO EUR 29.5 MILLION IN REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS A ROYALTY ON NET SALES.THERAPEUTICSMD INC - THERAPEUTICSMD IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD - CO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD-THERAMEX WILL BE RESPONSIBLE FOR CONDUCTING REGULATORY AND COMMERCIAL ACTIVITIES RELATED TO BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD INC - THERAMEX WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS FOR BIJUVA AND IMVEXXY OUTSIDE U.S., EXCLUDING CANADA AND ISRAEL.  Full Article

Therapeuticsmd Announces Fourth Quarter And Full-Year 2018 Financial Results
Friday, 22 Feb 2019 

Feb 21 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.17.Q4 REVENUE $5.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $5 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.17 -- REFINITIV IBES DATA.AS OF DECEMBER 31, 2018, COMPANY'S CASH ON HAND TOTALED APPROXIMATELY $161.6 MILLION.  Full Article

Therapeuticsmd Q3 Loss Per Share $0.16
Thursday, 8 Nov 2018 

TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 REVENUE $3.5 MILLION VERSUS $4.4 MILLION.Q3 REVENUE VIEW $4.4 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.21 -- THOMSON REUTERS I/B/E/S.BIJUVA COMMERCIAL LAUNCH PLANNED FOR 2Q 2019.ANNOVERA COMMERCIAL LAUNCH PLANNED FOR 4Q 2019.ENDED QUARTER WITH APPROXIMATELY $190 MILLION IN CASH AND APPROXIMATELY $75 MILLION IN OUTSTANDING DEBT.  Full Article

TherapeuticsMD Says FDA Has Granted AnnoveraTM Marketing Exclusivity As New Chemical Entity
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES THE FDA HAS GRANTED ANNOVERATM MARKETING EXCLUSIVITY AS A NEW CHEMICAL ENTITY.THERAPEUTICSMD - FIVE-YEAR NCE EXCLUSIVITY RUNS FOR FIVE YEARS FROM FDA APPROVAL OF NEW DRUG APPLICATION FOR ANNOVERA.  Full Article

TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr
Friday, 9 Mar 2018 

March 8 (Reuters) - Therapeuticsmd Inc ::THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR.THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE FOR COMPLETION OF FDA'S REVIEW IS OCTOBER 28, 2018 FOR TX-001HR.  Full Article

TherapeuticsMD Q4 Loss Per Share $0.10
Wednesday, 21 Feb 2018 

Feb 20 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $4.1 MILLION VERSUS $4.5 MILLION.  Full Article

TherapeuticsMD Submits New Drug Application For TX-001HR
Friday, 29 Dec 2017 

Dec 28 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR.THERAPEUTICSMD - EXPECTS TO LEARN OF ACCEPTANCE OF NDA FROM FDA ABOUT 74 DAYS AFTER NDA SUBMISSION.  Full Article

Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Therapeuticsmd Inc ::THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR.THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE SET OF MAY 29, 2018.THERAPEUTICSMD INC - COMPANY CURRENTLY PLANS TO LAUNCH TX-004HR IN Q3 OF 2018 IF APPROVAL OCCURS ON OR BEFORE PDUFA TARGET ACTION DATE.  Full Article

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR TX-004HR.THERAPEUTICSMD INC - COMPANY EXPECTS TO LEARN OF ACCEPTANCE OF NDA RESUBMISSION WITHIN 30 CALENDAR DAYS.  Full Article